Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results

Basit Öğe Kaydı
dc.authorscopusid57191447331
dc.authorscopusid56699810200
dc.contributor.authorArslan C.
dc.contributor.authorAtilla F.D.
dc.date.accessioned2023-03-22T19:47:45Z
dc.date.available2023-03-22T19:47:45Z
dc.date.issued2022
dc.departmentBelirleneceken_US
dc.description.abstractBackground: Little progress has been made, and there is an unmet medical need for treatment of metastatic gastric cancer (MGC). Docetaxel + cisplatin + 5-fluororacil (DCF) combination is an effective regimen with high rate of toxicity and is not well tolerated. We aimed to evaluate the efficacy and toxicity of a modified DCF (mDCF) combination regimen and capecitabine maintenance in MGC. Method: Data of MGC patients were treated with first-line mDCF regimen (two weekly docetaxel 60 mg/m2 day 1 iv, cisplatin 50 mg/m2 day 1 iv, 5-fluouracil 400 mg/m2 day 1 iv push, 2400 mg/m2; day 1–day 2 iv infusion, leucovorin 400 mg/m2 day 1 iv push) were recorded. Capecitabine maintenance was given as 2500 mg/m2/ day 1–day 14 po, every 3 weeks, to patients who do not have progressive disease and grade 3 treatment-related toxicity. A retrospective analysis was made. Results: Forty patients were included. Mean age was 53 ± 11. Thirty-two patients had de novo metastasis. All patients’ performance status was ECOG 1 or 2 (32/8). Median number of mDCF cycles given was 9 (min–max: 1–23). Overall response rate was 47.5%. Ten patients (25%) received capecitabine maintenance. Grade 3/4 toxicity was seen in 20 patients (50%). Hematologic grade 3/4 toxicity occurred in 13 patients (32.5%), and grade 3/4 neutropenia occurred in 11 patients (27.5%) and in 15 cycles. Nonhematologic grade 3/4 toxicity was seen in 7 patients (17.5%). Median follow-up time was 17.2 months. Median time to progression (TTP) was 10.8 ± 1.9 months (95% CI: 6.89–14.64). Median overall survival was 14.7 ± 1.73 months (95% CI: 11.30–18.10). Conclusions: mDCF protocol was a tolerable chemotherapy regimen for the first-line treatment of MGC with higher ORR and longer TTP compared to standard DCF protocol. Capecitabine maintenance might increase TTP. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.en_US
dc.identifier.doi10.1007/s00520-022-06859-0
dc.identifier.endpage4455en_US
dc.identifier.issn09414355
dc.identifier.issue5en_US
dc.identifier.pmid35106659en_US
dc.identifier.scopus2-s2.0-85124095241en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage4447en_US
dc.identifier.urihttps://doi.org/10.1007/s00520-022-06859-0
dc.identifier.urihttps://hdl.handle.net/20.500.14034/849
dc.identifier.volume30en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.relation.journalSupportive Care in Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdvanced gastric canceren_US
dc.subjectCapecitabine maintenanceen_US
dc.subjectModified DCFen_US
dc.subjectTreatmenten_US
dc.subjectcapecitabineen_US
dc.subjectcisplatinen_US
dc.subjectdocetaxelen_US
dc.subjectfluorouracilen_US
dc.subjectfolinic aciden_US
dc.subjectgranulocyte colony stimulating factoren_US
dc.subjectirinotecanen_US
dc.subjectantineoplastic agenten_US
dc.subjectcapecitabineen_US
dc.subjectcisplatinen_US
dc.subjectdocetaxelen_US
dc.subjectfluorouracilen_US
dc.subjecttaxoiden_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectanemiaen_US
dc.subjectantineoplastic protocolen_US
dc.subjectArticleen_US
dc.subjectcancer combination chemotherapyen_US
dc.subjectcancer patienten_US
dc.subjectcancer survivalen_US
dc.subjectcarcinomatous peritonitisen_US
dc.subjectcase reporten_US
dc.subjectchemotherapy induced nausea and vomitingen_US
dc.subjectclinical articleen_US
dc.subjectcomparative effectivenessen_US
dc.subjectdeathen_US
dc.subjectdisease free intervalen_US
dc.subjectdrug dose reductionen_US
dc.subjectdrug efficacyen_US
dc.subjectdrug fatalityen_US
dc.subjectdrug safetyen_US
dc.subjectdrug tolerabilityen_US
dc.subjectfatigueen_US
dc.subjectfebrile neutropeniaen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjecthumanen_US
dc.subjectinfection rateen_US
dc.subjectKaplan Meier methoden_US
dc.subjectkidney diseaseen_US
dc.subjectleukopeniaen_US
dc.subjectliver metastasisen_US
dc.subjectlung metastasisen_US
dc.subjectmaintenance chemotherapyen_US
dc.subjectmaleen_US
dc.subjectmetastasisen_US
dc.subjectmucosa inflammationen_US
dc.subjectmultiple cycle treatmenten_US
dc.subjectnauseaen_US
dc.subjectneuropathyen_US
dc.subjectneurotoxicityen_US
dc.subjectneutropeniaen_US
dc.subjectoverall response rateen_US
dc.subjectoverall survivalen_US
dc.subjectretrospective studyen_US
dc.subjectstomach canceren_US
dc.subjectthrombocytopeniaen_US
dc.subjecttreatment responseen_US
dc.subjectvomitingen_US
dc.subjectmiddle ageden_US
dc.subjectpathologyen_US
dc.subjectstomach tumoren_US
dc.subjecttreatment outcomeen_US
dc.subjectAdulten_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectCapecitabineen_US
dc.subjectCisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectFluorouracilen_US
dc.subjectHumansen_US
dc.subjectMiddle Ageden_US
dc.subjectRetrospective Studiesen_US
dc.subjectStomach Neoplasmsen_US
dc.subjectTaxoidsen_US
dc.subjectTreatment Outcomeen_US
dc.titleModified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy resultsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu